Scotland-based privately held company XstalBio has introduced new patented reconstitution technology, CentuRecon, to accelerate the delivery of biologic drugs at high concentration.
The technology facilitates the preparation of dry formulations of therapeutic proteins for injection at high concentration and production of foam-free solutions that maximise the deliverable dose.
Specifically beneficial for very high concentration and/or viscous solutions, CentuRecon is compatible with standard lyophilised formulations and diluents and with normal vials, cartridges or dual-chamber syringes.
XstalBio R&D director Barry Moore said CentuRecon provides a rapid, safe and reproducible method for preparing very high concentration protein solutions from dry powder formulations.
"We believe it will open up new clinical opportunities for biologics and become the reconstitution method of choice for R&D scientists," Moore added.
"CentuRecon is a good example of how XstalBio's R&D team are able to develop technologies that provide simple solutions to complex problems."
XstalBio has made the technology available for licensing.
